All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.

Requena MB, Protopopescu C, Stewart AC, van Santen DK, Klein MB, Jarrin I, Berenguer J, Wittkop L, Salmon D, Rauch A, Prins M, van der Valk M, Sacks-Davis R, Hellard ME, Carrieri P, Lacombe K; on behalf of the InCHEHC Collaboration

Global Infectious Disease Threats Hepatitis C HIV + AIDS

Chlamydia retesting remains low among young women in Australia: an observational study using sentinel surveillance data, 2018-2022.

Sexual + Reproductive Health Sexually Transmitted Infections (STI's)

Risk of primary incident hepatitis C infection following bacterial sexually transmissible infections among gay and bisexual men in Australia from 2016 to 2020.

Harney BL, Sacks-Davis R, Agius P, van Santen DK, Traeger MW, Wilkinson AL, Asselin J, Fairley CK, Roth N, Bloch M, Matthews GV, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS

Global Infectious Disease Threats Hepatitis C

Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy.

Hearps AC, Vootukuru N, Ebrahimnezhaddarzi S, Harney BL, Boo I, Nguyen L, Pavlyshyn D, Dietze PM, Drummer HE, Thompson AJ, Jaworowski A, Hellard ME, Sacks-Davis R, Doyle JS

Hepatitis C Injecting Drug Use

Innovation is needed to increase viral hepatitis testing globally.

Hellard ME, Pedrana A.

Hepatitis B Hepatitis C

Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020.

Harney BL, Sacks-Davis R, van Santen DK, Traeger MW, Wilkinson AL, Asselin J, Fairley CK, Roth N, Bloch M, Matthews GV, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS

Global Infectious Disease Threats Hepatitis C HIV + AIDS